Kalay2121. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258-62. doi: 10.1016/j.jacc.2006.07.052. |
2006 |
CVDL |
21 |
22 |
49 |
46.8 |
25 |
25 |
LMP, BC |
DOX, EPI |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
0 |
0 |
6 |
Cardinale2222. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition. Circulation. 2006;114(23):2474-81. doi: 10.1161/CIRCULATIONAHA.106.635144. |
2006 |
ENLP |
39 |
33 |
44 |
47 |
58 |
56 |
AL, BC, ES, HLMP, MLM, NHLMP |
EPI, IDA, DAU |
4 (7) |
3 (5) |
1 (2) |
1 (2) |
2 (3) |
2(4) |
NA |
NA |
18 (31) |
19 (34) |
12 |
Georgakopoulos2626. Georgakopoulos P, Roussou P, Matsakas E, Karavidas A, Anagnostopoulos N, Marinakis T, et al. Cardioprotective Effect of Metoprolol and Enalapril in Doxorubicin-Treated Lymphoma Patients: A Prospective, Parallel-Group, Randomized, Controlled Study with 36-Month Follow-Up. Am J Hematol. 2010;85(11):894-6. doi: 10.1002/ajh.21840. |
2010 |
MTPL |
19 |
20 |
49.1 |
51 |
40 |
42 |
HLMP, NHLMP |
DOX |
6 (15) |
10 (24) |
6 (15) |
10 (24) |
10 (25) |
14 (33) |
16 (40) |
17 (40) |
9 (23) |
8 (19) |
12 |
Georgakopoulos |
2010 |
ENLP |
19 |
21 |
49.1 |
47.4 |
40 |
43 |
HLMP, NHLMP |
DOX |
6 (15) |
14 (33) |
6 (15) |
3 (7) |
10 (25) |
11 (26) |
16 (40) |
20 (46) |
9 (23) |
9 (21) |
12 |
Salehi2727. Salehi R, Zamani B, Esfehani A, Ghafari S, Abasnezhad M, Goldust M. Protective Effect of Carvedilol in Cardiomyopathy Caused by Anthracyclines in Patients Suffering from Breast Cancer and Lymphoma. Am Heart Hosp J. 2011;9(2):95-8. doi: 10.15420/ahhj.2011.9.2.95. |
2011 |
CVDL * |
14 |
32 |
43.5 |
43.5 |
22 |
44 |
LMP, BC |
DOX, EPI |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
0 |
0 |
4 |
Dessì2828. Dessì M, Piras A, Madeddu C, Cadeddu C, Deidda M, Massa E, et al. Long-Term Protective Effects of the Angiotensin Receptor Blocker Telmisartan on Epirubicin-Induced Inflammation, Oxidative Stress and Myocardial Dysfunction. Exp Ther Med. 2011;2(5):1003-9. doi: 10.3892/etm.2011.305. |
2011 |
TMST |
18 |
19 |
53 |
52.9 |
24 |
25 |
NHLMP, BC, others |
EPI |
0 |
0 |
0 |
0 |
NA |
NA |
NA |
NA |
0 |
0 |
12 |
Kaya2929. Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya EG, Akpek M, et al. Protective Effects of Nebivolol Against Anthracycline-Induced Cardiomyopathy: A Randomized Control Study. Int J Cardiol. 2013;167(5):2306-10. doi: 10.1016/j.ijcard.2012.06.023. |
2013 |
NBVL |
18 |
27 |
50.5 |
51.4 |
18 |
27 |
BC |
DOX, EPI |
4 (22) |
6 (22) |
2 (11) |
2 (7) |
NA |
NA |
NA |
NA |
5 (28) |
7 (26) |
6 |
Bosch/OVERCOME3030. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, Caralt TM, et al. Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients with Malignant Hemopathies: The OVERCOME Trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355-62. doi: 10.1016/j.jacc.2013.02.072. |
2013 |
ENLP, CVDL |
21 |
18 |
50.9 |
49.7 |
45 |
45 |
AL, HLMP, NHLMP |
IDA, DAU |
8 (18) |
6 (13) |
3 (7) |
7(16) |
1 (2) |
3 (7) |
4 (9) |
13(29) |
4 (9) |
12(27) |
6 |
Elitok3131. Elitok A, Oz F, Cizgici AY, Kilic L, Ciftci R, Sen F, et al. Effect of Carvedilol on Silent Anthracycline-Induced Cardiotoxicity Assessed by Strain Imaging: A Prospective Randomized Controlled Study with Six-Month Follow-Up. Cardiol J. 2014;21(5):509-15. doi: 10.5603/CJ.a2013.0150. |
2014 |
CVDL |
40 |
40 |
52.9 |
54.3 |
40 |
40 |
BC |
DOX |
0 |
0 |
0 |
0 |
NA |
NA |
NA |
NA |
NA |
NA |
6 |
Akpek3232. Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, et al. Protective Effects of Spironolactone Against Anthracycline-Induced Cardiomyopathy. Eur J Heart Fail. 2015;17(1):81-9. doi: 10.1002/ejhf.196. |
2014 |
ESPL |
40 |
43 |
50.6 |
50 |
40 |
43 |
BC |
DOX, EPI |
0 |
0 |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
6 |
Gulati/PRADA2323. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): A 2 × 2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. Eur Heart J. 2016;37(21):1671-80. doi: 10.1093/eurheartj/ehw022. |
2016 |
CDST, MTPL |
32 |
32 |
50.8 |
50 |
32 |
32 |
BC |
EPI |
0 |
1 (3) |
0 |
0 |
NA |
NA |
7 (22) |
6 (20) |
23 (72) |
18 (60) |
6 |
Gulati/PRADA |
2016 |
CDST |
32 |
33 |
50.8 |
51.7 |
32 |
33 |
BC |
EPI |
0 |
5 (16) |
0 |
1 (3) |
NA |
NA |
7 (22) |
7 (22) |
23 (72) |
19 (60) |
6 |
Gulati/PRADA |
2016 |
MTPL |
32 |
32 |
50.8 |
50.5 |
32 |
32 |
BC |
EPI |
0 |
2 (6) |
0 |
1 (3) |
NA |
NA |
7 (22) |
5 (16) |
23 (72) |
22 (69) |
6 |
Jhorawat3333. Jhorawat R, Kumari S, Varma SC, Rohit MK, Narula N, Suri V, et al. Preventive Role of Carvedilol in Adriamycin-Induced Cardiomyopathy. Indian J Med Res. 2016;144(5):725-9. doi: 10.4103/ijmr.IJMR_1323_14. |
2016 |
CVDL |
9 |
4 |
38.7 |
43.89 |
27 |
27 |
NHLMP, HLMP, AL |
DOX |
NA |
NA |
0 |
0 |
NA |
NA |
NA |
NA |
NA |
NA |
6 |
Beheshti3434. Beheshti AT, Toroghi HM, Hosseini G, Zarifian A, Shandiz FH, Fazlinezhad A. Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial. Cardiology. 2016;134(1):47-53. doi: 10.1159/000442722. |
2016 |
CVDL |
40 |
30 |
39.9 |
42 |
40 |
30 |
BC |
DOX |
0 |
0 |
0 |
0 |
NA |
NA |
NA |
NA |
0 |
0 |
6 |
Nabati3535. Nabati M, Janbabai G, Baghyari S, Esmaili K, Yazdani J. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity. J Cardiovasc Pharmacol. 2017 May;69(5):279-85. doi: 10.1097/FJC.0000000000000470. |
2017 |
CVDL |
45 |
46 |
47.1 |
47.5 |
45 |
46 |
BC |
DOX |
5 (12) |
11 (27) |
5 (12) |
3 (7) |
NA |
NA |
NA |
NA |
0 |
0 |
6 |
Janbabai3636. Janbabai G, Nabati M, Faghihinia M, Azizi S, Borhani S, Yazdani J. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy. Cardiovasc Toxicol. 2017;17(2):130-9. doi: 10.1007/s12012-016-9365-z. |
2017 |
ENLP |
31 |
33 |
47 |
47.7 |
35 |
34 |
BC, HLMP, others |
DOX |
4 (11) |
6 (18) |
5 (14) |
3 (9) |
3 (9) |
4 (12) |
NA |
NA |
0 |
0 |
6 |
Abuosa3737. Abuosa AM, Elshiekh AH, Qureshi K, Abrar MB, Kholeif MA, Kinsara AJ, et al. Prophylactic Use of Carvedilol to Prevent Ventricular Dysfunction in Patients with Cancer Treated with Doxorubicin. Indian Heart J. 2018;70 Suppl 3(Suppl 3):S96-S100. doi: 10.1016/j.ihj.2018.06.011. |
2018 |
CVDL** |
29 |
83 |
40.4 |
46.1 |
38 |
116 |
BC, LMP, others |
DOX |
4 (10) |
14 (12) |
6 (16) |
21 (18) |
2 (5) |
6 (5) |
NA |
NA |
NA |
NA |
6 |
Cochera 3838. Cochera F, Dinca D, Bordejevic DA, Citu IM, Mavrea AM, Andor M, et al. Nebivolol Effect on Doxorubicin-Induced Cardiotoxicity in Breast Cancer. Cancer Manag Res. 2018;10:2071-81. doi: 10.2147/CMAR.S166481. |
2018 |
NBVL |
30 |
30 |
52 |
53 |
30 |
30 |
BC |
DOX |
0 |
0 |
0 |
0 |
3 (10) |
4 (13) |
3 (10) |
2 (6) |
0 |
0 |
6 |
Avila/CECCY2424. Avila MS, Ayub-Ferreira SM, Wanderley MRB Jr, Cruz FD, Brandão SMG, Rigaud VOC, et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. J Am Coll Cardiol. 2018;71(20):2281-90. doi: 10.1016/j.jacc.2018.02.049. |
2018 |
CVDL |
96 |
96 |
52.9 |
50.8 |
96 |
96 |
BC |
DOX |
9 (9) |
3 (3) |
5 (5) |
4 (4) |
2 (2) |
6 (6) |
26 (27) |
24 (25) |
0 |
0 |
6 |